# Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic

- Source: PR Newswire General Business
- Published: 2026-11-05T12:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/anaheim-bio-launches-with-40-million-series-a-financing-to-advance-ana-1-for-calcium-pyrophosphate-deposition-disease-into-the-clinic-302929917.html
- Canonical: https://groundlevelnews.com/story/anaheim-bio-launches-with-40-million-series-a-financing-to-advance-ana-677a56/

Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into 2028 with clinic entry in 2027 for ANA-1 LEIDEN, Netherlands, Nov. 5, 2026...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire General Business._